Ardelyx, Inc. ARDX

ARDX Company Overview

Ardelyx, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a concentration on conditions associated with chronic kidney disease (CKD) and disorders involving electrolyte balance and gastrointestinal function. Ardelyx’s principal revenue drivers are its commercialized therapies and related licensing arrangements, particularly products targeting hyperphosphatemia and irritable bowel syndrome with constipation (IBS-C).

The company’s lead commercial products include XPHOZAH (tenapanor) for the treatment of hyperphosphatemia in adults with CKD on dialysis and IBSRELA (tenapanor) for IBS-C. Ardelyx has positioned itself around therapies that target transport mechanisms in the gastrointestinal tract, leveraging proprietary discovery platforms centered on ion transport and renal-gastrointestinal biology. Founded in 2007 and headquartered in Waltham, Massachusetts, the company evolved from a clinical-stage biotechnology enterprise into a commercial-stage pharmaceutical company following U.S. regulatory approvals and commercialization efforts for tenapanor-based therapies.